Advances in novel parentral drug delivery systems

Asian Journal of Pharmaceutics

Volumn 4, Issue 3, 2010, Pages 193-199

  Patel, Rakesh ^a   Patel, Kaushal ^a  

^a GANPAT UNIVERSITY   (India)

Author keywords

Bioavailability; controlled release; drug targeting; parenteral drug delivery; sustained release; therapeutic index

Indexed keywords

ACTARIT; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; BROMOCRIPTINE; CLOZAPINE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; LEUPRORELIN; LIPOSOME; METHOTREXATE; NIOSOME; PACLITAXEL; POLYMER; QUININE; RIVASTIGMINE; SOLID LIPID NANOPARTICLE; TANSHINONE IIA; TOBRAMYCIN;

BRAIN MALARIA; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; KAPOSI SARCOMA; MYCOSIS; NANOEMULSION; NEOPLASM; PARENTERAL DRUG ADMINISTRATION; PARKINSONISM; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; SUSTAINED DRUG RELEASE;

EID: 78149381889     PISSN: 09738398     EISSN: 1998409X     Source Type: Journal    
DOI: 10.4103/0973-8398.72117     Document Type: Review

References (57)

1. Kapoor S. An overview on advanced parenteral drug delivery system in clinical disease management. Pharmainfo Net. 2007.
2. Panayiotis PC, Mahesh VC, Robert S. Advances in lipid nanodispersions for parenteral drug delivery and targetting. Science 2008;60:757-67.
3. Collins GL, Feichtinger N, Wärnheim T. Are lipid emulsions the drug delivery solution?. Mod Drug Discov 2000;3:44-8.
4. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-72.
5. Attama AA, Reichl S. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008;355:307-13.
6. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 2008;356:333-44.
7. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2008;71:161-72.
8. Wong HL. Solid lipid nanoparticles for antitumor drug delivery. In: Amiji M, editor. Nanotechnology for Cancer Therapy. USA: CRC Press; 2006. p. 714-76.
9. Shenoy VS, Vijay IK, Murthy RSR. Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles. J Pharm Pharmacol 2005;57:411-22.
10. Zhang X, Miao J, Yuan H. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 2008;361:239-44.
11. Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr CM. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm 2004;57:55-162.
12. Lu W, He LC, Wang CH, Li YH, Zhang SQ. The Use of Solid Lipid Nanoparticles to Target a Lipophilic Molecule to the Liver after Intravenous Administration to Mice. Int J Biological Macromol 2008;43:320-4.
13. Müller RH, Keck CM. Drug delivery to the brain-realization by novel drug carriers. J Nanosci Nanotechnol 2004;4:471-83.
14. Panyam J, Chavanpatil M. Lipid-derived nanoparticles for brain-targeted drug delivery. PCT 2008:WO2008024753.
15. Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007;59:935-40.
16. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting, J Control Release 2008;127:97-109.
17. Zhang W, Liu J, Li S, Chen M, Liu H. Preparation and evaluation of stealth Tashinone IIA-loaded solid lipid nanoparticles: influence of Poloxamer 188 coating on phagocytic uptake. J Microencapsul 2008;25:203-9.
18. Liu W, He Z, Liang J. Preparation and characterization of novel fluorescent nanocomposite particles: CdSe/ZnS core-shell quantum dots loaded solid lipid nanoparticles. J Biomed Mater Res. 2008;84:1018-25.
19. Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 2007;59:505-21.
20. Ye J, Wang Q, Zhou X, Zhang N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm 2008;352:273-9.
21. Zhang W, Liu J, Li S, Chen M, Liu H. Preparation and evaluation of stealth Tashinone IIA-loaded solid lipid nanoparticles: influence of Poloxamer 188 coating on phagocytic uptake. J Microencapsul 2008;25:203-09.
22. Dianzani C, Cavalli R, Zara GP, Gallicchio M, Lombardi G, Gasco MR, et al. Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells. Br J Pharmacol 2006;148: 648-56.
23. Weyhers H, Ehlers S, Hahn H, Souto EB, Müller RH. Solid lipid nanoparticles (SLN) - effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie 2006;61:539-44.
24. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004;58:445-55.
25. Moreau M, Abdellaoui KS, Schneider, Boisramc B, Gurny R. Controlled delivery of metoclopramide using an injectable semi-solid poly(ortho ester) for veterinary application. Int J Pharm 2002;248:31-7.
26. Dunn R. The Atrigel Drug Delivery System. In: Drugs and the Pharmaceutical Sciences. New York, MA: Dekker Series; 2003. p. 647-55.
27. Gentner G. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 2001;72:203-15.
28. Murdan S. Organogels in drug delivery. Expert Opin Drug Deliv 2005;2:489-505.
29. Chow HF, Zhang J, Lo CM. Improving the gelation properties of 3,5-diaminobenzoate-based organogelators in aromatic solvents with additional aromatic-containing pendants. Tetrahedron 2007;63:363-73.
30. Anda V, Leroux JC. Organogels and their use in drug delivery - A review. J Contro Release 2007;125:179-92.
31. Rossi J. Principles in the development of intravenous lipid emulsions. In: Wasan K. editor. Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery. Hoboken, New Jersey: Wiley-Interscience; 2007. p. 88-123.
32. Torchilin VP. Lipid-based parenteral drug delivery systems: biological implications. In: Wasan K, editor. Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery. Hoboken, New Jersey: Wiley-Interscience; 2007. p. 48-87.
33. Tadros T, Izquierdo P, Esquena J, Solans C. Formation and stability of nanoemulsions. Adv. Colloid Interface Sci 2004;109:303-18.
34. Rabinow BE. Nanosuspensions in drug delivery. Nature Rev 2004;3: 785-96.
35. Sarker DK. Engineering of nanoemulsions for drug delivery. Cur Drug Deliv 2005;2:297-310.
36. Shafiq-un-Nabi S, Shakeel F, Talegaonkar S, Ali J, Baboota S, Ahuja A, et al. Formulation development and optimization using nanoemulsion technique: a technical note. AAPS Pharm Sci Tech 2007;8:28.
37. Rons R, Carrera I, Caelles J, Rouch J, Panizza P. Formation and properties of miniemulsions formed by microemulsions dilution. Adv Colloid Interface Sci 2003;106:129-43.
38. Rabinow B, Kipp J, Papadopoulos P, Wong J, Glosson J, Gass J, et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 2007;339:251-60.
39. Moschwitzer J, Muller RH. New method for the effective production of ultrafine drug nanocrystals. J Nanosci Nanotechnol 2006;6:3145-53.
40. Mouton JW, Van PA, Beule K, Van VA, Donnelly JP, Soons PA. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob. Agents Chemother 2006;50:4096-102.
41. Patel RP. Niosomes: An Unique Drug Delivery System. Pharmainfo.net. 2007.
42. Shahiwala A, Misra AN. Studies in topical application of niosomally entrapped nimesulide. J Pharm Pharmaceu Sci 2002;5:220-5.
43. Tamizharasi S, Dubey A, Rathi V, Rathi JS. Development and characterization of niosomal drug delivery of Gliclazide. J Young Pharm 2009;1:205-09.
44. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res 2007;24:1029-46.
45. Doijad RC, Manvi FV, Swati S, Rony MS. Niosomal drug delivery of Cisplatin: Development and characterization. Indian Drugs 2008;45:713-8.
46. Ismail AA, Sanaa A, Gizawy E, Fouda MA, Donia AM. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. AAPS PharmSci Tech 2007;8:1-7.
47. Roopa K, Mamatha GC, Subramanya G, Udupa N. Preparation, characterization and tissue disposition of niosomes containing Isoniazid. Rasayan J Chem 2008;1:224-7.
48. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007;24:1-16.
49. Zamboni WC. Liposomal, nanoparticle and conjugated formulation of anticancer agents. Clin Cancer Res 2005;11:8230-34.
50. Mamot C, Drummond DC, Hong K, Kirlotin DB, Park JW. Liposome based approaches to overcome anticancer drug resistance. Drug Resist Update 2003;6:271-9.
51. Pastorino F, Brignole C, Marimpietri D. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003;63:86-92.
52. Brouckaert P, Takahashi N, Van Tiel ST. Tumor necrosis factor-a augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int J Cancer 2004;109:442-8.
53. Straubinger RM, Arnold RD, Zhou R. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res 2004;24:397-404.
54. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine in to the brain to treat Alzheimer's disease. Brain Res 2008;1200:159-68.
55. Rathod S, Deshpanden SG. Design and evaluation of liposomal formulation of pilocarpine nitrate. In J Pharm Sci 2010;72:155-60.
56. Samad A, Sultana Y, Aqil M. Liposomal Drug Delivery Systems: An update review. Curr Drug Deliv 2007;4:297-305.
57. www.azonano.com (Parenteral Drug Delivery III: Novel Parenteral Products, Devices, and Insulin).